NFKB1 and AL amyloidosis: To date, multiple NFκB inhibitors were evaluated in clinical to treat various cancer types including prostate, renal and colorectal cancers, melanoma and leukaemia whereas the JAK/STAT inhibitors were also tested for their anti‐cancer efficacy in ovarian, brain, prostate, pancreatic and neurologic cancers and multiple myeloma.6